Pricing Treatments Cost-Effectively When They Have Multiple Indications: Not Just a Simple Threshold Analysis
Preprint
Abstract
Background: Economic evaluations of treatments increasingly employ price-threshold analyses. When a treatment has multiple indications, standard price-threshold analyses can be overly simplistic. We examine how rules governing indication-specific prices and reimbursement decisions impact value-based price analyses. Methods: We analyze a two-stage game between two players: the therapy’s manufacturer and payer purchasing it for patients. First, the manufacturer selects a price(s) that may be indication-specific. Then, the payer decides whether to provide reimbursement at the offered price(s). We assume known indication-specific demand. The manufacturer seeks to maximize profit, requiring non-negative profit. The payer seeks to maximize total population incremental net monetary benefit and will not pay more than their willingness-to-pay threshold. We consider game variants defined by constraints on the manufacturer’s ability to price and payer’s ability to provide reimbursement differentially by indication. Results: When the manufacturer and payer can both make indication-specific decisions, the problem simplifies to single-indication price-threshold analyses, and the manufacturer captures all the consumer surplus. When the manufacturer is restricted to one price and the payer must make an all-or-nothing reimbursement decision, the selected price is a weighted average of indication-specific threshold prices such that reimbursement of the more valuable indications subsidize reimbursement of the less valuable indications. With a single price and indication-specific coverage decisions, the manufacturer may select a high price and fewer patients receive treatment than in the first-best solution. However, there are also cases when the manufacturer selects a low price resulting in reimbursement for all indications and positive consumer surplus. Conclusions: When multiple indications exist for a given treatment, economic evaluations including price-threshold analyses should carefully consider jurisdiction-specific rules regarding pricing and reimbursement decisions.Keywords
All Related Versions
- Published version: Medical Decision Making, 43 (7-8), 914.
This publication has 19 references indexed in Scilit:
- Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2018
- Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?PharmacoEconomics, 2018
- The Challenge of Conditional Reimbursement: Stopping Reimbursement Can Be More Difficult Than Not Starting in the First Place!Value in Health, 2017
- Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling studyThe Lancet Global Health, 2014
- Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neovascular Macular DegenerationOphthalmology, 2014
- A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirusHuman Vaccines & Immunotherapeutics, 2013
- Racial Variation in the Cost-Effectiveness of Chemotherapy for Prostate CancerJournal of Oncology Practice, 2011
- Optimal clinical trial design using value of information methods with imperfect implementationHealth Economics, 2009
- The Value of Implementation and the Value of Information: Combined and Uneven DevelopmentMedical Decision Making, 2007
- Service delivery should be funded centrallyBMJ, 2007